– First human proof-of-concept data from exoIL-12™ program confirmed desired product profile and enabled dose selection for further evaluation in patients – – On track to report biomarker, safety and clinical anti-tumor efficacy results in cancer patients in mid-2021 for exoSTING™ and by year-end for exoIL-12 –
– First human proof-of-concept data from exoIL-12™ program confirmed desired product profile and enabled dose selection for further evaluation in patients –
– On track to report biomarker, safety and clinical anti-tumor efficacy results in cancer patients
in mid-2021 for exoSTING™ and by year-end for exoIL-12 –
– Data from two novel engineered exosome therapeutic programs to be presented at AACR 2021,
including initial clinical data for exoIL-12 accepted as late-breaking abstract –
CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today reported fourth quarter and full year 2020 financial results and operational progress.
“The past year was tremendously productive for Codiak as we brought our first two programs into the clinic, the first ever engineered exosome therapeutic candidates to be tested in humans, and completed a successful initial public offering,” said Douglas E. Williams, Ph.D., President and Chief Executive Officer of Codiak. “The early data from our exoIL-12 program have provided validation of our approach and propel us into what we anticipate will be an exciting year ahead, with multiple data read-outs and the initiation of a third clinical program expected.”
Fourth Quarter 2020 and Recent Highlights
- Reported initial pharmacokinetic/pharmacodynamic and tolerability data from randomized, placebo-controlled healthy volunteer portion of the exoIL-12 Phase 1 clinical trial and selected pharmacological dose and regimen to carry forward into assessment in patients with cutaneous T cell lymphoma (CTCL)
- Progressed with subject dosing in the Phase 1/2 clinical trial of exoSTING for the treatment of advanced/metastatic, recurrent and injectable solid tumors
- Continued to advance exoASO™-STAT6 for the intravenous treatment of myeloid-rich cancers through IND-enabling studies
- Closed IPO in October 2020, raising $74.4 million in net proceeds
- Published manuscript detailing the exoIL-12 preclinical program in Molecular Cancer Therapeutics
- Published manuscript highlighting versatility of the engEx Platform in the online edition of Molecular Therapy
- Closed follow-on public offering in February 2021, raising $62.0 million in net proceeds
Anticipated Milestones and Events
- Late-breaking abstract poster presentation of the full pharmacokinetic/pharmacodynamic and tolerability data from healthy volunteer portion of the exoIL-12 Phase 1 clinical trial at the American Association for Cancer Research (AACR) Annual Meeting, to be held April 10-15, 2021
- Poster presentation of preclinical data from the exoASO-STAT6 program at the AACR Annual Meeting, to be held April 10-15, 2021
- Safety and preliminary pharmacodynamics and efficacy data from exoSTING Phase 1/2 clinical trial in patients with solid tumors expected mid-2021
- Investigational New Drug (IND) application filing for exoASO-STAT6 program to enable initiation of clinical trials anticipated during the second half of 2021
- Biomarker, safety and preliminary pharmacodynamics and efficacy data in CTCL patients from exoIL-12 Phase 1 trial expected by year-end 2021
Fourth Quarter and Full Year 2020 Financial Results
Total revenues for the quarter ended December 31, 2020 were $1.6 million, compared to $0.2 million for the same period in 2019. Total revenues for the year ended December 31, 2020 were $2.9 million, compared to $0.4 million for the same period in 2019. These increases were primarily due to revenue recognized in connection with our collaboration with Sarepta Therapeutics.
Net loss for the quarter ended December 31, 2020 was $18.0 million, compared to a net loss of $21.6 million for the same period in 2019. Net loss for the year ended December 31, 2020 was $91.7 million, compared to a net loss of $78.0 million for the same period in 2019. Net loss for the quarter and year was driven primarily by clinical development, general and administrative, and personnel expenses, and ongoing development of the engEx Platform.
Research and development expenses were $13.3 million for the quarter ended December 31, 2020 compared to $17.7 million for the same period in 2019. The decrease in research and development expenses was driven primarily by the timing of external manufacturing expenditures in the prior year.
Research and development expenses were $74.0 million for the year ended December 31, 2020 compared to $59.5 million for the same period in 2019. The year-over-year increase was primarily driven by an increase in license milestones, personnel costs, and clinical development expenses related to the initiation of the exoIL-12 and exoSTING clinical trials in September 2020.
General and administrative expenses were $5.9 million for the quarter ended December 31, 2020 compared to $4.3 million for the same period in 2019. The increase was driven primarily by an increase in personnel costs and costs associated with transitioning to a public company.
General and administrative expenses were $19.9 million for the year ended December 31, 2020 compared to $21.0 million for the same period in 2019. The year-over-year decrease was primarily driven by a decrease in consulting, accounting and legal fees.
As of December 31, 2020, Codiak had cash and cash equivalents of approximately $88.9 million. Subsequent to year end, Codiak closed a public offering in February 2021, raising $62.0 million in net proceeds. Based on our current operating plan, we expect our cash and cash equivalents as of December 31, 2020, together with the net proceeds from our follow-on public offering in February 2021, will enable us to fund our operating expenses and capital expenditure requirements through the end of 2022.
About Codiak BioSciences
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, among other things, statements concerning the development and therapeutic potential of exoSTING and exoIL-12, including timing of release of data, statements concerning the development of exoASO-STAT6, including the timing of initiation of its clinical program, statements regarding the capabilities and potential of Codiak’s engEx Platform and engineered exosomes generally and Codiak’s financial guidance including cash runway . Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of these risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Codiak’s Annual Report on Form 10-K for the year ended December 31, 2020, and in subsequent filings with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties and other important factors in Codiak’s subsequent filings with the Securities and Exchange Commission. All information in this press release is current as of the date of this report, and Codiak undertakes no duty to update this information unless required by law.
[tables to follow]
CODIAK BIOSCIENCES, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
| DECEMBER 31, | ||||||||
| 2020 | 2019 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 88,915 | $ | 10,316 | ||||
| Investments | — | 73,065 | ||||||
| Restricted cash | — | 367 | ||||||
| Prepaid expenses and other current assets | 4,843 | 10,370 | ||||||
| Total current assets | 93,758 | 94,118 | ||||||
| Property and equipment, net | 31,410 | 17,626 | ||||||
| Restricted cash, net of current portion | 4,170 | 4,170 | ||||||
| Operating right-of-use assets | 22,003 | — | ||||||
| Other non-current assets | — | 48 | ||||||
| Total assets | $ | 151,341 | $ | 115,962 | ||||
| Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 2,018 | $ | 2,381 | ||||
| Accrued expenses | 8,870 | 15,818 | ||||||
| Deferred revenue | 5,281 | 742 | ||||||
| Deferred rent | — | 814 | ||||||
| Operating lease liability | 1,482 | — | ||||||
| Total current liabilities | 17,651 | 19,755 | ||||||
| Long-term liabilities: | ||||||||
| Deferred revenue, net of current portion | 57,416 | 54,870 | ||||||
| Note payable, net of discount | 24,960 | 9,572 | ||||||
| Deferred rent, net of current portion | — | 9,814 | ||||||
| Operating lease liability, net of current portion | 36,540 | — | ||||||
| Other long-term liabilities | 207 | — | ||||||
| Total liabilities | 136,774 | 94,011 | ||||||
| Commitments and contingencies (Note 10) | ||||||||
| Series A redeemable convertible preferred stock, $0.0001 par value; No shares authorized, issued, or outstanding as of December 31, 2020; 33,200,000 shares authorized, issued and outstanding as of December 31, 2019; liquidation value as of December 31, 2019 of $44,169 | — | 44,169 | ||||||
| Series B redeemable convertible preferred stock, $0.0001 par value; No shares authorized, issued, or outstanding as of December 31, 2020; 21,400,000 shares authorized; 20,520,828 shares issued and outstanding as of December 31, 2019; liquidation value as of December 31, 2019 of $80,874 | — | 81,108 | ||||||
| Series C redeemable convertible preferred stock, $0.0001 par value; No shares authorized, issued, or outstanding as of December 31, 2020; 20,204,100 shares authorized; 20,204,079 shares issued and outstanding as of December 31, 2019; liquidation value as of December 31, 2019 of $89,507 | — | 89,507 | ||||||
| Stockholders’ equity (deficit): | ||||||||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of December 31, 2020; no shares authorized, issued or outstanding as of December 31, 2019; | $ | — | $ | — | ||||
| Common stock, $0.0001 par value; 150,000,000 shares authorized as of December 31, 2020; 120,000,000 shares authorized as of December 31, 2019; 18,787,579, and 2,997,040 shares issued and outstanding as of December 31, 2020 and 2019, respectively | 2 | — | ||||||
| Additional paid-in capital | 302,655 | 2 | ||||||
| Accumulated other comprehensive income | — | 43 | ||||||
| Accumulated (deficit) | (288,090 | ) | (192,878 | ) | ||||
| Total stockholders’ equity (deficit) | 14,567 | (192,833 | ) | |||||
| Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) | $ | 151,341 | $ | 115,962 | ||||
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share data)
| THREE MONTHS ENDED DECEMBER 31, | YEAR ENDED DECEMBER 31, | |||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
| Revenue: | ||||||||||||||||
| Collaboration revenue | $ | 1,639 | $ | 150 | $ | 2,915 | $ | 388 | ||||||||
| Total revenue | 1,639 | 150 | 2,915 | 388 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 13,328 | 17,706 | 73,981 | 59,501 | ||||||||||||
| General and administrative | 5,919 | 4,253 | 19,852 | 21,039 | ||||||||||||
| Total operating expenses | 19,247 | 21,959 | 93,833 | 80,540 | ||||||||||||
| Loss from operations | (17,608 | ) | (21,809 | ) | (90,918 | ) | (80,152 | ) | ||||||||
| Other (expense) income: | ||||||||||||||||
| Interest income | 7 | 354 | 253 | 1,500 | ||||||||||||
| Interest expense | (710 | ) | (297 | ) | (1,906 | ) | (300 | ) | ||||||||
| Other income | 353 | 114 | 906 | 992 | ||||||||||||
| Total other (expense) income, net | (350 | ) | 171 | (747 | ) | 2,192 | ||||||||||
| Net loss | $ | (17,958 | ) | $ | (21,638 | ) | $ | (91,665 | ) | $ | (77,960 | ) | ||||
| Cumulative dividends on redeemable convertible preferred stock | (534 | ) | (3,454 | ) | (10,831 | ) | (13,701 | ) | ||||||||
| Net loss attributable to common stockholders | $ | (18,492 | ) | $ | (25,092 | ) | $ | (102,496 | ) | $ | (91,661 | ) | ||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (1.14 | ) | $ | (8.37 | ) | $ | (16.18 | ) | $ | (30.66 | ) | ||||
| Weighted average common shares outstanding, basic and diluted | 16,233,377 | 2,996,942 | 6,332,841 | 2,989,423 | ||||||||||||
| Comprehensive loss: | ||||||||||||||||
| Net loss | $ | (17,958 | ) | $ | (21,638 | ) | $ | (91,665 | ) | $ | (77,960 | ) | ||||
| Other comprehensive (loss) income: | ||||||||||||||||
| Unrealized (loss) gain on investments, net of tax of $0 | — | (20 | ) | (43 | ) | 52 | ||||||||||
| Total other comprehensive (loss) income | — | (20 | ) | (43 | ) | 52 | ||||||||||
| Comprehensive loss | $ | (17,958 | ) | $ | (21,658 | ) | $ | (91,708 | ) | $ | (77,908 | ) | ||||
Investor Contact: Christopher Taylor VP, Investor Relations and Corporate Communications T: 617-949-4220 E: investor@codiakbio.com Media Contact: Lindy Devereux Scient PR T: 646-515-5730 E: media@codiakbio.com
